MedPath

Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Not Applicable
Terminated
Conditions
Prostatic Hyperplasia
Urinary Retention
Acute Disease
Registration Number
NCT00563654
Lead Sponsor
Hospital Authority, Hong Kong
Brief Summary

The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
48
Inclusion Criteria
  • Aged 50 or above
  • Admitted for AUR due to BPH with PVR of 500 ml or more
Exclusion Criteria
  • Previous history of TURP
  • Use of alpha blockers within recent 8 months
  • Renal impairment (serum creatinine >140 umol/l)
  • Poor premorbid state

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Successful rate of Trial Without Catheter (TWOC) at phase 1At discharge after TWOC (at the end phase one)
Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1From the end of phase one to eight months after successful TWOC (the end of phase 2)
Secondary Outcome Measures
NameTimeMethod
Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOCFrom the time of treatment drug administration to the end of phase 1
Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)At the end of phase I (discharge after TWOC) and at the end of phase 2

Trial Locations

Locations (1)

North District Hospital

🇨🇳

Hong Kong, China

© Copyright 2025. All Rights Reserved by MedPath